1、 彭湾,曹红.高病毒载量慢性乙型肝炎抗病毒治疗研究进展[J].新医学,2022,53(8):551-554. 彭湾,曹红.高病毒载量慢性乙型肝炎抗病毒治疗研究进展[J].新医学,2022,53(8):551-554.
2、 王静,闫涛涛,冯亚丽,等.母亲HBV DNA 载量对宫内传播及胎儿窘迫的影响[J].中华肝脏病杂志,2022, 30(8):873-878. 王静,闫涛涛,冯亚丽,等.母亲HBV DNA 载量对宫内传播及胎儿窘迫的影响[J].中华肝脏病杂志,2022, 30(8):873-878.
3、 PENG T T,CAI Q E,YANG M,et al.Epidemiological trends and virological traits of hepatitis B virus infection in pregnant women and neonates[J].Arch Virol,2019,164(5):1335-1341. PENG T T,CAI Q E,YANG M,et al.Epidemiological trends and virological traits of hepatitis B virus infection in pregnant women and neonates[J].Arch Virol,2019,164(5):1335-1341.
4、 WU C H,HUANG W C,CHEN C H,et al.Outcomes of hepatitis B immunoglobulin and hepatitis B vaccination in high-risk newborns born to HBeAg-positive mothers[J].Biomed J,2022,45(5):798-805. WU C H,HUANG W C,CHEN C H,et al.Outcomes of hepatitis B immunoglobulin and hepatitis B vaccination in high-risk newborns born to HBeAg-positive mothers[J].Biomed J,2022,45(5):798-805.
5、 赵红萍,周鸿良,王悦.孕早期胎盘HBV感染的危险因素分析[J].中国预防医学杂志,2019,20(9):858-861. 赵红萍,周鸿良,王悦.孕早期胎盘HBV感染的危险因素分析[J].中国预防医学杂志,2019,20(9):858-861.
6、 张宝芳,程明亮,张权,等.贵州地区HBeAg阳性乙型肝炎病毒高载量孕妇母婴阻断的临床研究[J].中华肝脏病杂志,2018, 26(12):945-950. 张宝芳,程明亮,张权,等.贵州地区HBeAg阳性乙型肝炎病毒高载量孕妇母婴阻断的临床研究[J].中华肝脏病杂志,2018, 26(12):945-950.
7、 VERONESE P,DODI I,ESPOSITO S,et al.Prevention of vertical transmission of hepatitis B virus infection[J].World J Gastroenterol,2021,27(26):4182-4193. VERONESE P,DODI I,ESPOSITO S,et al.Prevention of vertical transmission of hepatitis B virus infection[J].World J Gastroenterol,2021,27(26):4182-4193.
8、 BOUCHERON P,LU Y,YOSHIDA K,et al.Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates:A systematic review and meta-analysis[J].Lancet Infect Dis,2021,21(1):85-96. BOUCHERON P,LU Y,YOSHIDA K,et al.Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates:A systematic review and meta-analysis[J].Lancet Infect Dis,2021,21(1):85-96.
9、 王璐,代晶芳,张国梅.HBV高病毒载量孕妇与新生儿宫内感染的相关性分析[J].中华医院感染学杂志,2018,28(4):586-589,597. 王璐,代晶芳,张国梅.HBV高病毒载量孕妇与新生儿宫内感染的相关性分析[J].中华医院感染学杂志,2018,28(4):586-589,597.
10、 YAN L B,CHEN E Q,BAI L,et al.Efficacy of entecavir treatment for up to 96 weeks in nucleoside-naive HBeAg-positive chronic hepatitis B patients with high viral load[J].Clin Res Hepatol Gastroenterol,2015,39(3):366-372. YAN L B,CHEN E Q,BAI L,et al.Efficacy of entecavir treatment for up to 96 weeks in nucleoside-naive HBeAg-positive chronic hepatitis B patients with high viral load[J].Clin Res Hepatol Gastroenterol,2015,39(3):366-372.
11、 FUNG S,GORDON S C,KROSTEV Z,et al.Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load(≥ 9 log10 copies/ml)[J].Liver Int,2015,35(2):422-428. FUNG S,GORDON S C,KROSTEV Z,et al.Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load(≥ 9 log10 copies/ml)[J].Liver Int,2015,35(2):422-428.
12、 KIM G A,LIM Y S,HAN S,et al.High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J].Gut,2018,67(5):945-952. KIM G A,LIM Y S,HAN S,et al.High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J].Gut,2018,67(5):945-952.
13、 黄燕,杜冰莹,谢青.HBeAg阳性且高病毒载量ALT正常慢性HBV感染患者应尽早抗病毒治疗[J].中华肝脏病杂志,2023,31(3):233-237. 黄燕,杜冰莹,谢青.HBeAg阳性且高病毒载量ALT正常慢性HBV感染患者应尽早抗病毒治疗[J].中华肝脏病杂志,2023,31(3):233-237.
14、 YOO J J,PARK S Y,MOON J E,et al.Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase[J].Clin Mol Hepatol,2023,29(2):482-495. YOO J J,PARK S Y,MOON J E,et al.Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase[J].Clin Mol Hepatol,2023,29(2):482-495.
15、 HONG Y M,YOON K T.Definition and management of the immune tolerance phase in chronic hepatitis B[J].Korean J Gastroenterol,2022,79(4):156-160. HONG Y M,YOON K T.Definition and management of the immune tolerance phase in chronic hepatitis B[J].Korean J Gastroenterol,2022,79(4):156-160.
16、 刘春云,常丽仙,李俊义,等.HBV感染免疫耐受期肝组织炎症和纤维化的影响因素分析[J].临床肝胆病杂志, 2022,38(9):2005-2009. 刘春云,常丽仙,李俊义,等.HBV感染免疫耐受期肝组织炎症和纤维化的影响因素分析[J].临床肝胆病杂志, 2022,38(9):2005-2009.
17、 WANG Y F,ZHAO M,ZHAO L,et al.HBx-induced HSPA8 stimulates HBV replication and suppresses ferroptosis to support liver cancer progression[J]. Cancer Res,2023,83(7):1048-1061. WANG Y F,ZHAO M,ZHAO L,et al.HBx-induced HSPA8 stimulates HBV replication and suppresses ferroptosis to support liver cancer progression[J]. Cancer Res,2023,83(7):1048-1061.
18、 吴勇,况钦,周梦瑶,等.SNHG12在乙肝病毒X蛋白诱导肝癌发生中的作用研究[J].广州医药,2023,54(1):16-24,43. 吴勇,况钦,周梦瑶,等.SNHG12在乙肝病毒X蛋白诱导肝癌发生中的作用研究[J].广州医药,2023,54(1):16-24,43.
19、 SIVASUDHAN E,BLAKE N,LU Z,et al.Hepatitis B viral protein HBx and the molecular mechanisms modulating the hallmarks of hepatocellular carcinoma:A comprehensive review[J].Cells,2022,11(4):741. SIVASUDHAN E,BLAKE N,LU Z,et al.Hepatitis B viral protein HBx and the molecular mechanisms modulating the hallmarks of hepatocellular carcinoma:A comprehensive review[J].Cells,2022,11(4):741.
20、 QU S,JIN L,HUANG H,et al.A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis[J]. BMC Cancer,2021,21(1):686. QU S,JIN L,HUANG H,et al.A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis[J]. BMC Cancer,2021,21(1):686.
21、 ODA C,KAMIMURA K,SHIBATA O,et al.HBx and YAP expression could promote tumor development and progression in HBV-related hepatocellular carcinoma[J].Biochem Biophys Rep,2022(32):101352. ODA C,KAMIMURA K,SHIBATA O,et al.HBx and YAP expression could promote tumor development and progression in HBV-related hepatocellular carcinoma[J].Biochem Biophys Rep,2022(32):101352.
22、 GLITSCHER M,HILDT E,BENDER D.Hepatitis B und C:Mechanismen der virusinduzierten leberpathogenese und tumorentstehung[Hepatitis B and C:mechanisms of virus-induced liver pathogenesis and tumorigenesis][J].Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz,2022,65(2):228-237. GLITSCHER M,HILDT E,BENDER D.Hepatitis B und C:Mechanismen der virusinduzierten leberpathogenese und tumorentstehung[Hepatitis B and C:mechanisms of virus-induced liver pathogenesis and tumorigenesis][J].Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz,2022,65(2):228-237.
23、 JIANG Y,HAN Q,ZHAO H,et al.The mechanisms of HBV-induced hepatocellular carcinoma[J].J Hepatocell Carcinoma,2021(8):435-450. JIANG Y,HAN Q,ZHAO H,et al.The mechanisms of HBV-induced hepatocellular carcinoma[J].J Hepatocell Carcinoma,2021(8):435-450.
24、 áLVAREZ E G,DEMEULEMEESTER J,OTERO P,et al.Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture[J].Nat Commun,2021,12(1):6910. áLVAREZ E G,DEMEULEMEESTER J,OTERO P,et al.Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture[J].Nat Commun,2021,12(1):6910.
25、 GUO M,ZHAO L,JIANG C,et al.Multiomics analyses reveal pathological mechanisms of HBV infection and integration in liver cancer[J].J Med Virol,2023,95(8):e28980. GUO M,ZHAO L,JIANG C,et al.Multiomics analyses reveal pathological mechanisms of HBV infection and integration in liver cancer[J].J Med Virol,2023,95(8):e28980.
26、 PODLAHA O,WU G,DOWNIE B,et al.Genomic modeling of hepatitis B virus integration frequency in the human genome[J].PLoS One,2019,14(7):e0220376. PODLAHA O,WU G,DOWNIE B,et al.Genomic modeling of hepatitis B virus integration frequency in the human genome[J].PLoS One,2019,14(7):e0220376.
27、 GIOSA D,LOMBARDO D,MUSOLINO C,et al.Mitochondrial DNA is a target of HBV integration[J].Commun Biol,2023,6(1):684. GIOSA D,LOMBARDO D,MUSOLINO C,et al.Mitochondrial DNA is a target of HBV integration[J].Commun Biol,2023,6(1):684.
28、 YIN G,ZHANG N,BUHE A,et al.Risk factors of secondary infection/recurrence after ablation for liver cancers:A systemic review and meta-analysis[J].J Cancer Res Ther,2022,18(5):1352-1359. YIN G,ZHANG N,BUHE A,et al.Risk factors of secondary infection/recurrence after ablation for liver cancers:A systemic review and meta-analysis[J].J Cancer Res Ther,2022,18(5):1352-1359.
29、 LI L,LI B,ZHANG M.HBV DNA levels impact the prognosis of hepatocellular carcinoma patients with microvascular invasion[J].Medicine(Baltimore),2019,98(27):e16308. LI L,LI B,ZHANG M.HBV DNA levels impact the prognosis of hepatocellular carcinoma patients with microvascular invasion[J].Medicine(Baltimore),2019,98(27):e16308.
30、 YANG Y,WEN F,LI J,et al.A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib[J].Liver Int, 2015,35(9):2147-2154. YANG Y,WEN F,LI J,et al.A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib[J].Liver Int, 2015,35(9):2147-2154.
31、 王燕. 乙肝病毒载量对中晚期肝癌患者生存率的影响[J].世界最新医学信息文摘,2021,21(91):37-38. 王燕. 乙肝病毒载量对中晚期肝癌患者生存率的影响[J].世界最新医学信息文摘,2021,21(91):37-38.
32、 谢露,刘光伟,郭会军.HBV DNA载量水平与乙型肝炎相关肝癌指标的相关性分析及其对预后的影响[J].中西医结合肝病杂志,2023,33(10):925-929. 谢露,刘光伟,郭会军.HBV DNA载量水平与乙型肝炎相关肝癌指标的相关性分析及其对预后的影响[J].中西医结合肝病杂志,2023,33(10):925-929.
33、 孟金霞,卢喜玲,别文倩,等.乙肝肝硬化并发原发性肝癌的相关危险因素分析[J].实用癌症杂志,2022,37(5):777-779. 孟金霞,卢喜玲,别文倩,等.乙肝肝硬化并发原发性肝癌的相关危险因素分析[J].实用癌症杂志,2022,37(5):777-779.
34、 郭俊霞,魏晓华.乙肝肝硬化患者合并原发性肝癌的危险因素及预后分析[J].陕西医学杂志,2019,48(7):850-852. 郭俊霞,魏晓华.乙肝肝硬化患者合并原发性肝癌的危险因素及预后分析[J].陕西医学杂志,2019,48(7):850-852.
35、 CHOI W M,KIM G A,CHOI J,et al.Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B[J].Gut,2024,73(4):649-658. CHOI W M,KIM G A,CHOI J,et al.Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B[J].Gut,2024,73(4):649-658.
36、 ILOEJE U H,YANG H I,SU J,et al.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load[J]. Gastroenterology, 2006,130(3):678-686. ILOEJE U H,YANG H I,SU J,et al.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load[J]. Gastroenterology, 2006,130(3):678-686.
37、 CHEN C J,YANG H I,SU J,et al.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006,295(1):65-73. CHEN C J,YANG H I,SU J,et al.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006,295(1):65-73.
38、 FRAGER S Z,SCHWARTZ J M.Hepatocellular carcinoma:epidemiology,screening,and assessment of hepatic reserve[J]. Curr Oncol,2020,27(Suppl 3):S138-S143. FRAGER S Z,SCHWARTZ J M.Hepatocellular carcinoma:epidemiology,screening,and assessment of hepatic reserve[J]. Curr Oncol,2020,27(Suppl 3):S138-S143.
39、 GORDON S C,KRASTEV Z,HORBAN A,et al.Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load[J].Hepatology,2013, 58(2):505-513. GORDON S C,KRASTEV Z,HORBAN A,et al.Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load[J].Hepatology,2013, 58(2):505-513.
40、 LOK A S,TRINH H,CAROSI G,et al.Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-na?ve patients with chronic hepatitis B[J]. Gastroenterology,2012,143(3):619-628. LOK A S,TRINH H,CAROSI G,et al.Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-na?ve patients with chronic hepatitis B[J]. Gastroenterology,2012,143(3):619-628.
41、 European Association for the Study of the Liver.Electronic address:Easloffice@easloffice.eu;European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J].J Hepatol,2017,67(2):370-398. European Association for the Study of the Liver.Electronic address:Easloffice@easloffice.eu;European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J].J Hepatol,2017,67(2):370-398.
42、 王磊,赵鹏,石盾.不同剂量恩替卡韦治疗高病毒载量e抗原阳性乙型肝炎的效果及安全性分析[J].解放军医药杂志,2018,30(6):72-74,95. 王磊,赵鹏,石盾.不同剂量恩替卡韦治疗高病毒载量e抗原阳性乙型肝炎的效果及安全性分析[J].解放军医药杂志,2018,30(6):72-74,95.
43、 周珲堃,江建宁,苏明华,等.恩替卡韦与替诺福韦酯治疗高病毒载量慢性乙型肝炎患者的效果分析[J].临床肝胆病杂志,2022,38(3):532-536. 周珲堃,江建宁,苏明华,等.恩替卡韦与替诺福韦酯治疗高病毒载量慢性乙型肝炎患者的效果分析[J].临床肝胆病杂志,2022,38(3):532-536.
44、 王辉. 恩替卡韦与替诺福韦酯治疗高病毒载量慢性乙型肝炎患者的临床效果分析[J].系统医学,2022,7(16):100-103,132. 王辉. 恩替卡韦与替诺福韦酯治疗高病毒载量慢性乙型肝炎患者的临床效果分析[J].系统医学,2022,7(16):100-103,132.
45、 HUANG M,ZHONG J,LU C,et al.Genotypic resistance remains a concern in chronic hepatitis B patients with high viral load after lamivudine and adefovir combination therapy[J].Pharmgenomics Pers Med,2019(12):297-303. HUANG M,ZHONG J,LU C,et al.Genotypic resistance remains a concern in chronic hepatitis B patients with high viral load after lamivudine and adefovir combination therapy[J].Pharmgenomics Pers Med,2019(12):297-303.
46、 张蕾. 扶正化瘀胶囊联合恩替卡韦和熊去氧胆酸对HBeAg阳性高病毒载量乙肝肝硬化患者抗病毒疗效及肝功能、肝纤维化和炎症反应的影响[J].药物评价研究,2019,42(4):739-742. 张蕾. 扶正化瘀胶囊联合恩替卡韦和熊去氧胆酸对HBeAg阳性高病毒载量乙肝肝硬化患者抗病毒疗效及肝功能、肝纤维化和炎症反应的影响[J].药物评价研究,2019,42(4):739-742.
47、 陈潇潇. 恩替卡韦和替比夫定治疗高病毒载量慢性乙型肝炎患者的远期疗效分析[J].当代医学,2020,26(30):184-186. 陈潇潇. 恩替卡韦和替比夫定治疗高病毒载量慢性乙型肝炎患者的远期疗效分析[J].当代医学,2020,26(30):184-186.
48、 蔡晓娟,朱晓红,薛红.替比夫定和恩替卡韦在高病毒载量乙肝患者治疗中的远期疗效比较[J].现代消化及介入诊疗,2020,25(9):1194-1196. 蔡晓娟,朱晓红,薛红.替比夫定和恩替卡韦在高病毒载量乙肝患者治疗中的远期疗效比较[J].现代消化及介入诊疗,2020,25(9):1194-1196.
49、 郭丽玲. 分析恩替卡韦与替诺福韦二吡呋酯治疗高病毒载量慢性乙型肝炎患者的效果[J].北方药学,2023,20(5):47-49. 郭丽玲. 分析恩替卡韦与替诺福韦二吡呋酯治疗高病毒载量慢性乙型肝炎患者的效果[J].北方药学,2023,20(5):47-49.
50、 王贵强,王福生,成军,等.慢性乙型肝炎防治指南(2015年版)[J].实用肝脏病杂志,2016,19(3):389-400. 王贵强,王福生,成军,等.慢性乙型肝炎防治指南(2015年版)[J].实用肝脏病杂志,2016,19(3):389-400.
51、 任丹丹,刘娜,周路路,等.HBV相关肝细胞癌的危险因素[J].临床肝胆病杂志,2020,36(7):1634-1638. 任丹丹,刘娜,周路路,等.HBV相关肝细胞癌的危险因素[J].临床肝胆病杂志,2020,36(7):1634-1638.
52、 YANG Y,GAO J,TAN Y T,et al.Individual and combined effects of hepatitis B surface antigen level and viral load on liver cancer risk[J]. J Gastroenterol Hepatol,2018,33(5):1131-1137. YANG Y,GAO J,TAN Y T,et al.Individual and combined effects of hepatitis B surface antigen level and viral load on liver cancer risk[J]. J Gastroenterol Hepatol,2018,33(5):1131-1137.
53、 曾红梅,蔡建强.中国肝癌诊治现状再思考[J].肝癌电子杂志,2021,8(2):23-25. 曾红梅,蔡建强.中国肝癌诊治现状再思考[J].肝癌电子杂志,2021,8(2):23-25.
